MediciNova discloses notice of allowance for new patent on MN-166 + Riluzole

MediciNova “announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166, or ibudilast, and riluzole for the treatment of amyotrophic lateral sclerosis. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover the use of the combination of MN-166 and riluzole for treating a patient diagnosed with ALS when administered in a tablet, a capsule, or a liquid dosage form. The allowed claims specifically cover the use of the combination of MN-166 and riluzole for slowing progression of disease in a patient diagnosed with ALS when administered in a tablet, a capsule, or a liquid dosage form. The allowed claims cover a wide range of doses and a range of dosing regimens for both MN-166 and riluzole.”